Archive · 5 Dec 2025
Constipation Drug May Slow Kidney Decline
Doctors found that a medicine used to treat constipation might also help people with kidney problems.
They tested this medicine, called lubiprostone, on people with a condition called chronic kidney disease (CKD).
The medicine seemed to slow down the worsening of kidney function.
This is important because there are currently no medicines that can fix kidney function in CKD patients.
The medicine works by helping good bacteria in the gut and improving tiny energy factories in our cells called mitochondria.
The doctors plan to do more tests to see if this medicine can help even more people.
This discovery could lead to new treatments not just for kidney problems, but also for other conditions where these energy factories don't work well.
Lubiprostone, a constipation drug, may slow kidney function decline in CKD patients.
Phase II clinical trial showed lubiprostone slowed decline in kidney function compared to placebo.
The drug boosts spermidine production, enhancing mitochondrial activity and gut bacteria.
Researchers plan to expand the study with a Phase 3 clinical trial and identify biomarkers for personalized treatment.
Findings suggest potential for new treatments for conditions involving mitochondrial dysfunction.
- Who
- Research team led by Professor Takaaki Abe at Tohoku University Graduate School of Medicine
- What
- Lubiprostone, a constipation drug, may slow kidney function decline in CKD patients
- When
- Study details published in Science Advances (exact date not specified)
- Where
- Multicenter study across nine medical facilities in Japan
- Why
- Constipation disrupts intestinal microbiota, worsening kidney function; treating constipation may improve kidney health
- Drug
- Lubiprostone
- Condition
- Chronic Kidney Disease (CKD)
- Study Type
- Phase II Clinical Trial (LUBI-CKD TRIAL)
- Participants
- 150 individuals with moderate CKD
- Key Finding
- Lubiprostone slows decline in kidney function
- Mechanism
- Boosts spermidine production, enhancing mitochondrial activity
- Next Steps
- Phase 3 clinical trial and biomarker identification
- Journal
- Science Advances